GAIN-(L): Efficacy and Biomarker Findings of RG7160 (GA201), a Novel, Dual-Acting Monoclonal Antibody (mab) Designed to Enhance Antibody-Dependent Cellular Cytotoxicity (ADCC), in Combination with First-Line Cisplatin and Pemetrexed in Metastatic Nonsquamous NSCLC.